Wednesday, June 15, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST


There are many different types of extracellular vesicles (EVs). Different subpopulations of exosomes, microvesicles and apoptotic bodies have been found to vary in size, composition and intracellular origin.

Within the last decade, cell-secreted EVs have been isolated from most of the fluids of the body, with many laboratories from around the world showing that their composition of lipids, proteins, messenger and micro RNAs are cell-type specific and subject to changes in pathological scenarios. As a result, EVs have been widely studied as a biological source to unravel low invasive biomarkers for predicting, diagnosing and monitoring diseases.
However, despite the many technological advances [click to continue…]


Abcam is hosting a free webinar titled “Developing durable miRNA biomarker technologies for microbial carcinogenesis in resource poor settings”.

Live Webinar Details

Wednesday, November 4, 2015
16:00-17:00 CET/ 15:00-16:00 GMT/ 10:00-11:00 EST/ 07:00-08:00 PST

Register here:

Webinar Summary:

Currently, more than half of the global cancer burden occurs in low-and middle-income countries, with 40% of those cancers related to infection. MicroRNA profiling has tremendous potential for the diagnosis and prognosis of a broad range of these cancers, as miRNA remains stable in many accessible sample matrices- such as blood, urine, saliva, and tissue- making them ideal biomarkers.

The full promise of miRNA profiling has yet to be realized, largely due to the limited throughput of existing technologies, lack of compatibility with samples containing PCR inhibitors, and errors introduced during sample preparation.

However, as Jordan Plieskatt and lab have seen in their work on NPC and CCA, while there are several multiplexing technologies for miRNA [click to continue…]


Abcam acquires FireflyBio - LogosCambridge UK, 21 January, 2015: Abcam plc, a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc (“Firefly”) (“the Acquisition”) on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, which is payable in cash on completion, will be funded from Abcam’s existing resources [1].

Firefly has developed a novel multiplex assay platform for the detection of biomarkers, based on a microfabrication technology developed by the founders at Massachusetts Institute of Technology and has developed its first product for detection of microRNAs (miRNAs). Firefly has 15 employees and is based in Cambridge, Massachusetts.

The Acquisition fits well with Abcam’s strategy outlined in September to establish new growth platforms and supports the Company’s mission to enable scientists to discover more. Firefly will strengthen [click to continue…]

Incoming search terms for this article: